CONGRESS PRESENTATIONS
IDWeekTM 2024
Los Angeles, California
October 16-19, 2024
-
ViiV-Sponsored Data
-
Cabotegravir Prevention
Baker DM, et al.
Change in Healthcare Professional’s Identification, Counseling, and Adherence with Black Women for Long-Acting Cabotegravir (CAB LA) for PrEP Across Women’s Health, Primary Care, and Infectious Diseases Sites: Findings from the EBONI Study
Holder H, et al.
Patient Experiences at Month 6 after Initiation of Cabotegravir Long-Acting (CAB LA) for PrEP in the First Male Gender Concordant Implementation Science Trial (PILLAR) in the US
Kerrigan D, et al.
Social Determinants of Health and Side Effects Significantly Predict Pre-Exposure Prophylaxis (PrEP) Preferences for Every 2 Month Long-Acting Injectable vs. Daily Oral PrEP among Cisgender Women in the United States and the Dominican Republic
Khan TH, et al.
Improvement in Provider Experiences from Baseline to Month 12 with Integrating Cabotegravir Long-Acting (CAB LA) for PrEP into Care in an Implementation Science Trial (PILLAR)
Metzner AA, et al.
Awareness and preferences for every 2 month long-acting injectable HIV Pre-Exposure Prophylaxis (PrEP) versus daily oral PrEP among cisgender women in the United States and the Dominican Republic
Mills A, et al.
Cabotegravir Long-Acting for Pre-Exposure Prophylaxis (PrEP): Real World Data on On-Time Dosing, HIV Testing and HIV Acquisition from the OPERA Cohort
Poteat T, et al.
Opportunities for PrEP Awareness and Engagement: A Survey among Healthcare-Seeking Cisgender Women in the US
Ramgopal M, et al.
Real-World Use of Cabotegravir Long-Acting for Pre-Exposure Prophylaxis: Data from Trio Health Cohort
-
Cabotegravir Treatment
Altamirano JA, et al.
Characteristics of Women Initiating CAB+RPV LA in the OPERA Cohort
Brogan AP, et al.
People with HIV in the US switching to cabotegravir + rilpivirine long-acting (CAB+RPV LA) from oral antiretroviral therapy (ART) have numerous real-world benefits, including high adherence and treatment satisfaction
Gutner CA, et al.
Feasibility, Fidelity, and Effectiveness of Administering CABENUVA in Infusion Centers
Lackey PC, et al.
Improved Testing for Chronic Disease Among Long-Acting Injectable Versus Daily Oral Antiretroviral Therapy Users in the OPERA Cohort
-
Dolutegravir-based Regimens
Doblado-Maldonado A, et al.
Real-world Virologic and Safety Outcomes in People Living with HIV-1 Using Dolutegravir (DTG) + Lamivudine (3TC) in Asia Stratified by Viral Load (VL), Including in Individuals with High VLs
Huchet E, et al.
Real-world Experience with the Two-Drug Regimen Dolutegravir/Lamivudine for the Treatment of HIV-1 among Vulnerable People Living with HIV in Canada: Preliminary Results from a Chart Review Study
Jones CB, et al.
Evaluation of Weight Gain on Incident Hypertension among People Living with HIV-1 Receiving Dolutegravir (DTG)-Based Regimens or Comparator Antiretroviral Therapy (cART) in Randomized Clinical Trials through 96 Weeks
Short WR, et al.
Extrapolating Expected Efficacy, Safety, and Pharmacokinetics (PK) of Dolutegravir/Lamivudine (DTG/3TC) in Pregnant People Living with HIV-1 from Pregnancy Data with Combination DTG and/or 3TC Antiretroviral Therapies
Slim J, et al.
PAIRED - PAtIent Reported Experiences and perceiveD benefit of treatment with dolutegravir/lamivudine (DTG/3TC): a diverse sample of people with HIV-1 reporting high treatment satisfaction, good adherence, and high quality of life
-
Fostemsavir
Castagna A, et al.
Similar Efficacy, Safety and CD4 T-cell Increase up to Week 96 Observed with Fostemsavir (FTR)-Based Regimens in the BRIGHTE Study and Dolutegravir (DTG)-Based Regimens in the VIKING-3 Study in Individuals with Multidrug-Resistant (MDR) HIV-1
Spagnuolo V, et al.
CD4 T-cell, CD4/CD8 Ratio Improvement and a General Reduction in Inflammatory Biomarkers with Low-Level Viremia (LLV) up to Week 192 with Fostemsavir (FTR)-Based Regimens in Individuals with Multidrug-Resistant (MDR) HIV-1
-
-
ViiV-Supported & Collaborative Data
-
Plain Language Summaries
